Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Late Effects of Treatment Common in Gastroesophageal Cancer Survivors

TOP - April 2012, Vol 5, No 2 published on April 30, 2012 in Gastrointestinal Cancers

Patients with gastric or gastroesophageal cancer commonly experience long-term complications from treatment that compromise their quality of life (QOL), according to self-reported answers to an Internet-based survey questionnaire. Difficulty swallowing appears to be universal, and other problems range from dry mouth and taste changes to cardiovascular disease, according to a study presented at the 2012 American Society of Clinical Oncology Gastrointestinal Symposium held in San Francisco, California.

“Survivors…unanimously and voluntarily report significant health problems after treatment for gastroesophageal cancers. The data reported here are important for designing future studies of QOL, as well as patient counseling and comprehensive survivor care,” stated lead author James M. Metz, MD, Department of Radiation Oncology at University of Pennsylvania’s Abramson Cancer Center, Philadelphia, Pennsylvania.

The authors of this study utilized an Internet-based tool for creation of survivorship plans (available at www.livestrongcareplan.org and through the OncoLink Web site). The tool enables survivors to enter data regarding diagnosis and treatments and provides customized guidelines for future care. Patients who use this tool are asked about late effects associated with specific treatment and answer “yes,” “no,” or “I don’t know.” They are also asked to score toxicity using World Health Organization criteria.

Questions about late effects of treatment were answered by 66 survivors: 80% with esophageal cancer and 20% with gastric cancer. Median age was 55 years. Slightly less than two-thirds were female, and 93% were Caucasian. Average time from diagnosis was 3.8 years. Of the sample, 91% of those with esophageal cancer and 77% of those with gastric cancer underwent surgery; 79% and 85%, respectively, received chemotherapy; and 53% and 31%, respectively, were treated with radiation.

Late effects, in descending order from most common to least frequent, were difficulty swallowing (100%), dry mouth/taste changes (60%), cognitive changes (42%), dental changes (40%), tinnitus (36%), cardiovascular disease (35%; hypertension, 21%; hyperlipidemia, 13%; angina, 2%), sexual changes (28%), peripheral neuropathy (24%), and chronic lung disease (14%).

Related Items
FDA Grants Approval to Avapritinib for Patients with GIST
Web Exclusives published on January 13, 2020 in FDA Updates, Gastrointestinal Cancers, In the News, Rare Cancers
Lutathera (Lutetium Lu 177 Dotatate) First Radioactive Drug Approved for Gastroenteropancreatic Neuroendocrine Tumors
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in Drug Updates, FDA Updates, Gastrointestinal Cancers
Investigational Angiogenesis Inhibitor Ramucirumab Improves Survival as Second-Line Treatment
Wayne Kuznar
TOP - May 2014, Vol 7, No 2 published on June 10, 2014 in Gastrointestinal Cancers
Upper GI Cancers: Are We Getting Value for the Money?
Cristi Radford, MS, CGC
TOP - August 2011 Vol 4, No 5 published on August 25, 2011 in Gastrointestinal Cancers
For Overweight Patients, Dosing Chemotherapy Based on Total Body Weight Does Not Lead to More Toxicities
Wayne Kuznar
Web Exclusives published on February 17, 2011 in Gastrointestinal Cancers
Last modified: April 27, 2020